FAERS数据库中5α还原酶抑制剂不良反应报告综述:对后非那雄胺综合征的启示
结果显示非那雄胺1mg剂量报告的不良事件多于5mg,症状涉及性功能、皮肤、代谢及心理/神经等多个领域,部分超出既往长期对照研究已确立的不良事件范围。
要点
- 非那雄胺1mg报告的不良事件数多于5mg剂量。
- 报告的症状涵盖性功能、皮肤、代谢及心理/神经等多类。
- 部分投诉超出既往长期对照研究已确立的不良事件范围。
核心结论
- FAERS数据提示非那雄胺暴露与多种症状报告相关,尤其是较年轻男性使用1mg剂量者相比更年长男性使用5mg剂量者报告更多。
- 许多投诉超出既往长期对照研究已确立的不良事件范围。
研究设计与样本
- 共识别2048例单药治疗病例:非那雄胺1mg 1581例,5mg 240例,剂量未报告226例。
- 每份FAERS报告有16个类别需填写,但并非所有报告均完整填写。
- 统计分析比较非那雄胺1mg与5mg两个剂量间的感兴趣变量。
主要发现
- 从2011年至2014年,涉及1mg剂量的不良事件报告显著增加,可能与标签变更有关。
- 非那雄胺使用报告中包含多种性功能不良事件,如性欲减退、勃起功能障碍和射精投诉。
- 其他常见不良事件包括皮肤、代谢及心理和/或神经投诉。
- 1mg剂量的不良事件报告数多于5mg剂量。
- 一例度他雄胺报告背痛,通常不归因于后非那雄胺综合征。
临床怎么用
- 临床医生在处方5α还原酶抑制剂时应关注性功能、心理/神经及代谢等相关症状报告。
- 对于使用1mg非那雄胺的年轻男性,需警惕多种不良事件报告的可能性。
局限性
- FAERS报告存在不完整性,并非所有报告均完整填写16个类别。
- 原文未报告因果关系推断、报告率或对照比较的统计显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify reports made to the Food and Drug Administration Adverse Event Reporting System (FAERS), create a demographic of patient reports, and examine the cluster of symptoms to correlate consistency of postfinasteride syndrome (PFS) complaints. PFS is a provisional diagnosis encompassing a cluster of sexual, physical, and psychological and/or neurologic symptoms associated with 5-alpha reductase inhibitor use that emerge or continue after discontinuation of medication. MATERIALS AND METHODS: FAERS dataset of 5-alpha reductase inhibitors from April 2011 to October 2014 was obtained. Each FAERS report had 16 categories for completion, but not every report was fully completed. Statistical analysis compared variables of interest between the 2 doses of finasteride (1 mg vs 5 mg). RESULTS: From FAERS, 2048 monotherapy cases were identified: 1581 of finasteride 1 mg, 240 of finasteride 5 mg, and 226 of unreported doses. Possibly related to labeling changes, from 2011 to 2014, there was a significant increase in adverse events (AEs) reported involving 1 mg dosing. Finasteride use was reported with many sexual AEs including diminished libido, erectile dysfunction, and ejaculatory complaints. Other common AEs included dermatologic, metabolic, and psychological and/or neurologic complaints. There were more AE reports with the 1 mg dose than the 5 mg dose. One case of dutasteride reported back pain, not generally attributed to PFS. CONCLUSION: FAERS data suggests that finasteride exposure is reported with a diverse collection of symptoms, particularly in younger men on 1 mg dosage compared to older men on 5 mg. Many of these complaints fall well out of the realm of previously established AEs from long-term controlled studies.
引用
- Baas WR, Butcher MJ, Lwin A, et al. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome. Urology. 2018. PMID: 29960004. doi:10.1016/j.urology.2018.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。